Kodiak Sciences Valuation
Is KOD * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of KOD * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate KOD *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate KOD *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for KOD *?
Key metric: As KOD * is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is KOD *'s PB Ratio? | |
|---|---|
| PB Ratio | 1.8x |
| Book | US$185.37m |
| Market Cap | US$324.98m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -1.1x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does KOD *'s PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.3x | ||
LAB B Genomma Lab Internacional. de | 2.2x | 19.8% | Mex$24.9b |
JSPR Jasper Therapeutics | 4x | -16.4% | US$330.8m |
2487 Cutia Therapeutics | 2x | 49.4% | HK$2.6b |
2616 CStone Pharmaceuticals | 5x | 49.9% | HK$2.5b |
KOD * Kodiak Sciences | 1.8x | -7.0% | Mex$325.0m |
Price-To-Book vs Peers: KOD * is good value based on its Price-To-Book Ratio (1.8x) compared to the peer average (3.3x).
Price to Book Ratio vs Industry
How does KOD *'s PB Ratio compare vs other companies in the Global Biotechs Industry?
| 87 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 87 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: KOD * is good value based on its Price-To-Book Ratio (1.8x) compared to the Global Biotechs industry average (2.3x).
Price to Book Ratio vs Fair Ratio
What is KOD *'s PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 1.8x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate KOD *'s Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$110.00 | Mex$88.75 -19.3% | 34.4% | Mex$122.88 | Mex$40.96 | n/a | 6 |
| Nov ’25 | n/a | Mex$53.17 0% | 15.7% | Mex$58.00 | Mex$38.67 | n/a | 4 |
| Oct ’25 | n/a | Mex$53.17 0% | 15.7% | Mex$58.00 | Mex$38.67 | n/a | 4 |
| Sep ’25 | n/a | Mex$49.72 0% | 17.7% | Mex$55.94 | Mex$37.29 | n/a | 3 |
| Aug ’25 | n/a | Mex$58.39 0% | 31.9% | Mex$83.41 | Mex$33.37 | n/a | 4 |
| Jul ’25 | n/a | Mex$58.39 0% | 31.9% | Mex$83.41 | Mex$33.37 | n/a | 4 |
| Jun ’25 | n/a | Mex$58.39 0% | 31.9% | Mex$83.41 | Mex$33.37 | n/a | 4 |
| May ’25 | n/a | Mex$70.57 0% | 45.2% | Mex$116.23 | Mex$33.21 | n/a | 4 |
| Apr ’25 | n/a | Mex$62.13 0% | 51.2% | Mex$115.98 | Mex$33.14 | n/a | 4 |
| Mar ’25 | n/a | Mex$44.76 0% | 24.7% | Mex$59.68 | Mex$34.10 | n/a | 4 |
| Feb ’25 | n/a | Mex$77.42 0% | 84.3% | Mex$206.45 | Mex$34.41 | n/a | 5 |
| Jan ’25 | n/a | Mex$74.94 0% | 87.0% | Mex$204.39 | Mex$34.06 | n/a | 5 |
| Dec ’24 | n/a | Mex$90.43 0% | 75.4% | Mex$206.70 | Mex$34.45 | n/a | 4 |
| Nov ’24 | n/a | Mex$71.97 0% | 46.8% | Mex$125.94 | Mex$35.98 | n/a | 4 |
| Oct ’24 | n/a | Mex$68.58 0% | 46.8% | Mex$120.01 | Mex$34.29 | n/a | 4 |
| Sep ’24 | n/a | Mex$68.58 0% | 46.8% | Mex$120.01 | Mex$34.29 | n/a | 4 |
| Aug ’24 | n/a | Mex$87.89 0% | 56.3% | Mex$169.02 | Mex$33.80 | n/a | 5 |
| Jul ’24 | n/a | Mex$192.12 0% | 54.4% | Mex$409.85 | Mex$68.31 | n/a | 8 |
| Jun ’24 | n/a | Mex$199.15 0% | 54.4% | Mex$424.85 | Mex$70.81 | n/a | 8 |
| May ’24 | n/a | Mex$202.23 0% | 54.4% | Mex$431.43 | Mex$71.90 | n/a | 8 |
| Apr ’24 | n/a | Mex$222.90 0% | 49.6% | Mex$455.28 | Mex$94.85 | n/a | 8 |
| Mar ’24 | n/a | Mex$217.56 0% | 49.6% | Mex$444.37 | Mex$92.58 | n/a | 8 |
| Feb ’24 | Mex$148.04 | Mex$245.28 +65.7% | 44.0% | Mex$463.52 | Mex$96.57 | n/a | 10 |
| Jan ’24 | n/a | Mex$245.28 0% | 44.0% | Mex$463.52 | Mex$96.57 | n/a | 10 |
| Dec ’23 | n/a | Mex$245.28 0% | 44.0% | Mex$463.52 | Mex$96.57 | n/a | 10 |
| Nov ’23 | n/a | Mex$246.56 0% | 32.0% | Mex$363.12 | Mex$100.87 | n/a | 9 |
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
IQVIA Holdings
US$36.6b
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQV *
US$3,880.00
7D
-11.8%
1Y
12.0%
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a